Sacubitril/valsartan (LCZ696) Significantly Reduces Aldosterone and Increases cGMP Circulating Levels in a Canine Model of RAAS Activation
J. P. Mochel, C. H. Tang, M. Peyrou, J. Giraudel, M. Danhof, D. Rigel
This study shows sacubitril/valsartan increases cGMP and reduces aldosterone in a canine RAAS activation model compared to placebo and other drugs.
bioRxiv · Oct 5, 2018Pharmacology & Toxicology